Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Bisoprolol

Preparation Calculator

Bisoprolol

Cardioselective Ξ²1 blocker

AdultBBHFHTN

Indication

HTN β€’ HFrEF (GDMT) β€’ AF rate control β€’ Post-MI context when indicated

At a glance

INDICATIONS (CORE USE)

**HTN**; **HFrEF** (evidence-based GDMT agent). **Cardioselective** β€” still **caution** in reactive airway disease.

ADULT DOSE (STANDARD)

**PO:** **start low** (e.g. **1.25–2.5 mg daily**) β†’ **slow up-titration** especially **HF** q **~2 weeks** to target per cardiology

MAX DOSE

**HF** targets often **10 mg daily** (rarely 20) β€” guideline/clinic specific

Route

PO

PEDIATRIC DOSE

Not standard β€” specialist if used

Do not miss

Must-not-miss safety points

Major warning

- Bradycardia / hypotension on titration - Acute decompensated HF β€” **DO NOT start** / **hold** if hypotension, shock, pulmonary edema needing IV support, or escalating inotropes - Bronchospasm β€” not asthma-safe

Indications

USE IF: HTN, HFrEF GDMT titration pathway, AF rate control. AVOID IF: Acute unstable bradycardia, uncompensated HF for new Ξ²-blocker initiation without ICU/cards plan.

Primary

  • Hypertension
  • HFrEF with **bisoprolol** (evidence-based GDMT)

Secondary

  • Atrial fibrillation β€” **rate control**
  • Ischemic heart disease / post-MI when Ξ²-blocker indicated

Dosing

STANDARD (ADULT PO)

**Once daily** typical β€” **HF** requires **gradual titration**

ADULT DOSE

**HF:** **1.25–2.5 mg daily** start β†’ **double q ~2 weeks** if tolerated toward **10 mg** goal. **HTN:** start **2.5–5 mg** β†’ titrate to **BP/HR**.

PEDIATRIC DOSE

N/A

MAX DOSE

Often **10 mg/day** in HF; HTN may use higher per label β€” verify

Practical Note

**Renal/hepatic** impairment: START lower per label.

Warnings

Clinical warnings

  • Beta1-selective β€” caution in asthma / bronchospasm; not asthma-proof at higher doses. HOLD if HR <50–55, SBP <90–100, symptomatic bradycardia, high-grade AV block, or acute decompensated HF with shock/hypoperfusion.
  • Cardioselective profile is not asthma-proof
  • Diabetes on insulin

Adverse effects

  • Bradycardia
  • fatigue
  • dizziness
  • worsening HF if started too fast

Contraindications

  • Acute cardiogenic shock
  • High-grade AV block (without pacing)
  • Sinus bradycardia with symptoms

Drug interactions

  • Verapamil / diltiazem: avoid or use extreme caution (bradycardia / AV block / hypotension / shock risk)
  • Digoxin: additive AV-node suppression / AV block risk
  • Insulin / sulfonylureas: masks hypoglycemia warning
  • Antiarrhythmics: additive bradycardia / conduction slowing

Special populations

Pediatrics

Not standard β€” specialist if used

Pregnancy

**Pregnancy:** use only if benefit > risk β€” **labetalol** often preferred for HTN. **

Lactation

** generally low oral bioavailability to infant β€” OB/peds if concern.

Renal impairment

**↓ clearance** in renal impairment β€” follow label for dose adjustment.

Hepatic impairment

Severe hepatic impairment β€” start low; monitor.

Elderly

Conservative titration β€” orthostasis and bradycardia.

Administration

PO with or without food per label.

Monitoring

  • Monitor: - Symptoms β†’ dizziness, syncope, fatigue
  • Recheck: - Reassess ECG / PR interval / AV block risk with symptoms, IV use, or dose escalation - Reassess dose / volume / cause within 48–72h after change - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - Hold if:
    - HR <50–55
    - SBP <90–100
    - Symptomatic bradycardia
    - Acute decompensated HF
    - Hypoperfusion / cardiogenic shock
    - Pulmonary edema requiring IV therapy

    Also hold:
    - High-grade AV block
    - Severe orthostasis

Overdose / toxicity

Clinical Picture

A) Mild β†’ bradycardia, hypotension, fatigue B) Moderate β†’ sustained bradycardia + hypotension Β± AV block C) Severe β†’ shock, high-grade AV block, seizures / coma (severe toxicity)

Immediate Actions

β€’ Airway + continuous monitoring first (ABCs, telemetry, BP) β€’ Bradycardia β†’ atropine β€’ Hypotension β†’ IV fluids β€’ Early β†’ IV calcium (CaCl2 / Ca-gluconate) β€’ Glucagon 3–5 mg IV β€’ Repeat or escalate glucagon β†’ infusion if responsive (often transient) β€’ Persistent shock β†’ HIET (insulin + dextrose) β€’ Monitor glucose + potassium closely β€’ Add vasopressors if shock persists β€’ Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) β€’ Refractory severe lipophilic toxicity β†’ IV lipid emulsion (toxicology-guided) β€’ Pacing β†’ symptomatic high-grade AV block β€’ ECMO β†’ refractory shock (per center) β€’ Severe / unstable β†’ ACLS + ICU / toxicology

Antidote

- Glucagon β†’ non-Ξ² pathway (often transient) - IV calcium β†’ inotropy / conduction support - HIET β†’ metabolic rescue (refractory shock) - IV lipid β†’ lipophilic toxicity (refractory / seizures)

Decontamination

β€’ Recent **oral** ingestion β†’ **activated charcoal** if **protected airway** and within **~1–2 h** (ingestion history + risk/benefit)

Escalation

- Wide QRS / ventricular arrhythmia β†’ sodium bicarbonate (membrane-stabilizing toxicity) - Pacing β†’ symptomatic high-grade AV block - ECMO β†’ refractory shock (per center)

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**HF:** **slow titration** β€” starting too high β†’ **worsening HF**.

Clinical pearls

**Evidence HF** agent β€” do not substitute with **random Ξ²-blocker**. *Ξ²-blockers (class):* **Start low, go slow.** **HF:** only **evidence-based agents** (**metoprolol succinate**, **bisoprolol**, **carvedilol**) for **HFrEF GDMT** β€” not all Ξ²-blockers interchangeable. **Rate control (AF)** vs **BP lowering** β€” titrate to the clinical target.

Beta-blocker safety

  • Titrate on schedule
  • HR/BP at each visit

Pharmacy Tool

Preparation Calculator

Bisoprolol 1 mg/mL oral suspension

suspension Β· oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

Hepatic metabolism + renal excretion of metabolites β€” **long duration** supports **QD** dosing.

Mechanism of action

**Ξ²1** antagonism with relative selectivity at usual doses.

Common brand names

Saudi Arabia

Concor, Cardicor

Global

Zebeta, (placeholder β€” verify local formulation)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Acute **aortic syndromes** and **thyrotoxic storm** are **protocol-driven** β€” Ξ²-blocker choice and targets are **team + guideline** specific.
  • Ξ²-blocker **GDMT for HFrEF** applies only to **evidence-based agents** β€” verify label and cardiology plan before substituting.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)
  • ACC / AHA / HFSA heart failure and hypertension guidance
  • ESC cardiovascular and arrhythmia guidelines where applicable
  • FDA / SFDA product labeling
  • Institutional ICU / toxicology protocols (overdose)

Do not miss

  • Teach **not to stop abruptly** after chronic use β€” taper when feasible
  • Titrate to **HR vs BP endpoint** (AF rate control often needs higher exposure than BP alone)
  • Titrate on schedule
  • HR/BP at each visit